Skip to content
Featured on Startup Fame

Peptris uses AI to accelerate preclinical drug discovery in Bengaluru

Peptris Technologies, a Bengaluru-based startup, is applying artificial intelligence to preclinical drug discovery, targeting oncology, inflammation, and rare diseases. The company’s platform combines unsupervised learning, generative AI, and large language models to design and optimize drug candidates, aiming to reduce time and cost compared to traditional methods.

Editor, Lazyfounder

Published Updated 2 min read

What Peptris does

Peptris Technologies is a Bengaluru-based startup focused on preclinical drug discovery using artificial intelligence. According to YourStory, the company applies unsupervised learning, generative AI, and large language models to design, optimize, and prioritize drug candidates for oncology, inflammation, and rare diseases. Its platform aims to improve speed, accuracy, and cost efficiency compared to traditional drug discovery methods.

How the platform works

The company’s proprietary AI platform identifies novel chemical entities, repurposes approved drugs, and rescues clinically validated molecules by predicting molecular properties. This reduces reliance on extensive wet-lab experimentation, according to the source. Peptris operates through a virtual R&D model, collaborating with contract research organizations, biotech partners, academic institutions, and pharmaceutical companies to advance its preclinical pipeline.

Portfolio and partnerships

Peptris has reportedly developed a range of AI-discovered drug candidates, including assets for rare diseases and cancer. The company has also achieved milestones through licensing partnerships and regulatory recognition, according to YourStory. Its team combines expertise in computational biology, medicinal chemistry, data science, and AI to deliver scalable drug discovery solutions.

Funding and team

Peptris has raised a total of $9 million in funding, with investors including Tenacity Ventures, Indian Angel Network, and Speciale Invest. The startup was founded in 2019 and has a core team of four co-founders: Narayanan Venkatasubramanian, Shridhar Narayanan, Amit Mahajan, and Anand Budni. The company is headquartered in Bengaluru and follows a B2B business model.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Peptris demonstrates how AI can compress the early stages of drug discovery, a process notoriously slow and capital-intensive. For founders in healthtech or AI-driven biotech, the company’s virtual R&D model and collaborations with CROs and pharma partners show a path to de-risk early-stage asset development without owning physical labs. The $9M funding round—led by deep-tech and biotech-focused investors—also signals growing confidence in AI-first drug discovery, which may encourage similar startups to seek funding. Operators in this space should note Peptris’ focus on regulatory milestones and licensing deals; these are tangible outputs that investors increasingly demand.

Sources

  1. yourstory.com
    Peptris Company Profile Funding & Investors

This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.

About the author

Editor, Lazyfounder

Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.

More stories by Tarun Mottlia

Get the LazyFounder Brief

Startup, funding and AI news in a five-minute read. Join the early-access list.

Lazy Founder - Powered by Blogy.in

Contact us

Have a story tip, correction or partnership idea?

Write to us at tarun.kumar@blogy.in or talk to the founder directly. We read every message.

Contact us